Featured Editorial

  1. RNA's Evolutionary Logic Is Quietly Rewriting The Future Of Therapeutics: A Conversation With Ahmet Berkyurek 12/3/2025

    RNA’s adaptive logic is reshaping how therapies are designed. Ahmet Berkyurek explains why embracing evolution—not engineering against it—may unlock the next generation of RNA medicines.

  2. Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next Chapter 11/25/2025

    Now, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance. 

  3. Rethinking The "3:1 Rule" In LNP Production 11/21/2025

    A new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.

  4. Emerging RNA Delivery Strategies For Solid Tumor Oncology 11/20/2025

    RNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.

  5. Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing 11/14/2025

    Here, a panel of experts at the RNA Leaders Conference gives a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.” 

  6. Innovation, Growth (and Happiness) Projected for Pharma 11/10/2025

    Not only is investment increasing in pharma, but innovation is propelling growth in multiple drug segments, and the people supporting this growth and innovation remain happy.

  7. The 9 Fastest-Growing Outsourcing Segments 11/7/2025

    Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

  8. Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next 11/6/2025

    NeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.

  9. Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy 11/4/2025

    Overcoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.

  10. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 11/3/2025

    Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.